Physician

Matthew Donald Kangas, MD

According to 2025 Medicare claims, Matthew Kangas, MD (NPI: 1750674222) practices anesthesiology in the Memphis, TN-MS-AR market, with the plurality of this provider's patient population coming from De Soto, MS. This provider's primary affiliated billing organization is PAIN CLINIC ASSOCIATES PLLC (NPI: 1306496567; TIN: 621168992) and primary practice location at 38671-5138.

Kangas' data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 2,633 traditional Medicare patients, billed 18,813 HCPCS/CPT codes, and received $931,589 in Medicare payments. The top billing code was G0481 (Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms). Part D data shows 1,557 prescription claims across 554 beneficiaries totaling $117,077 in drug costs, led by Buprenorphine (Buprenorphine). 2023 DME data shows 13 claims. Open Payments data shows 120 records totaling $8,759. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $26,122 to $931,589. Similarly, Part D prescription costs have moved sharply higher in recent years, from $4,342 to $117,077. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	N/R	N/R	N/R
2016	126	508	$26,122
2017	452	5,034	$273,127
2018	592	7,124	$413,546
2019	542	4,291	$466,430
2020	376	2,590	$259,347
2021	381	1,427	$84,840
2022	874	9,791	$447,985
2023	912	11,435	$468,439
2024	2,633	18,813	$931,589

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	65	101	$4,342
2016	132	322	$17,820
2017	262	1,400	$45,979
2018	322	1,293	$49,568
2019	241	1,116	$59,515
2020	233	1,546	$71,671
2021	149	397	$17,738
2022	328	1,623	$116,248
2023	464	2,132	$154,576
2024	554	1,557	$117,077

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	17	17	$17,364
2023	13	13	$13,189
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
G0481	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms	741	894	$152
99204	New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more	208	209	$115
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms	280	294	$110
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	661	2,480	$86
80307	Testing for presence of drug, by chemistry analyzers	2,321	4,549	$60

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Buprenorphine	Buprenorphine	120	3,332	$31,297
Belbuca	Buprenorphine Hcl	38	1,140	$20,975
Xtampza Er	Oxycodone Myristate	21	625	$9,207
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	197	5,487	$3,566
Gabapentin	Gabapentin	251	7,956	$3,451

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	120	$8,759	Abbott Laboratories
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Matthew Donald Kangas, MD?

Tedicare shows public-source Medicare data for Matthew Donald Kangas, MD (NPI 1750674222), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Matthew Donald Kangas, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Matthew Donald Kangas, MD?

Matthew Donald Kangas, MD is linked to PAIN CLINIC ASSOCIATES PLLC (billing NPI 1306496567) in the available physician profile data.

Does Matthew Donald Kangas, MD have Open Payments data?

Matthew Donald Kangas, MD has 120 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.